TY - JOUR T1 - [Tolerance and efficacy of atovaquone-proguanil for the treatment of paediatric imported Plasmodium falciparum malaria in France: clinical practice in a university hospital in Paris]. AU - Blondé,R, AU - Naudin,J, AU - Bigirimana,Z, AU - Holvoet,L, AU - Fenneteau,O, AU - Vitoux,C, AU - Bourdon,O, AU - Angoulvant,F, AU - Lorrot,M, AU - D'Ortenzio,E, AU - Bourrillon,A, AU - Le Bras,J, AU - Matheron,S, AU - Faye,A, Y1 - 2008/03/05/ PY - 2007/05/05/received PY - 2007/09/23/revised PY - 2007/10/14/accepted PY - 2008/3/7/pubmed PY - 2008/8/6/medline PY - 2008/3/7/entrez SP - 245 EP - 52 JF - Archives de pediatrie : organe officiel de la Societe francaise de pediatrie JO - Arch Pediatr VL - 15 IS - 3 N2 - UNLABELLED: Only few drugs for uncomplicated Plasmodium falciparum malaria are available in children. Atovaquone-proguanil is a recent antimalarial drug licensed in France for the uncomplicated P. falciparum malaria in adults. Few paediatric studies have evaluated atovaquone-proguanil in children for uncomplicated malaria in endemic area, but no study have evaluated this treatment for imported malaria. OBJECTIVE: To evaluate treatment by atovaquone-proguanil for uncomplicated and imported P. falciparum malaria in children. METHODS: We retrospectively evaluated the tolerance and the efficacy of atovaquone-proguanil in the children admitted in Robert-Debré Hospital (Paris) for a P. falciparum malaria. From January 2004 to December 2005, 48 children with a median age of 7,5 years (IQR 4-11) were treated with atovaquone-proguanil for a uncomplicated P. falciparum malaria, except for 5 children who had an isolated hyperparasitemia greater or equal to 5%. RESULTS: Atovaquone-proguanil was stopped for 3/48 children because of vomiting. Fever resolved in all the children between Day 3 and 7, following the beginning of the treatment. One child, with a favourable outcome, had a positive parasitemia at Day 4 equal to the initial parasitemia (0,1%). No late therapeutic failure was observed among the 24 children evaluated up to one month after starting treatment. CONCLUSION: Atovaquone-proguanil is an efficient and well-tolerated antimalarial treatment for uncomplicated P. falciparum malaria in children. The risk of vomiting should lead to a systematic initial hospitalisation of children treated with atovaquone-proguanil. SN - 0929-693X UR - https://www.unboundmedicine.com/medline/citation/18321692/[Tolerance_and_efficacy_of_atovaquone_proguanil_for_the_treatment_of_paediatric_imported_Plasmodium_falciparum_malaria_in_France:_clinical_practice_in_a_university_hospital_in_Paris]_ DB - PRIME DP - Unbound Medicine ER -